| B-CLL/SLL |
del 13q, 11q, 17p13, 6q21, trisomy 12 |
Very high-risk disease: 17p deletion and/or TP53 mutations High-risk disease: IGHV unmutated (without 17p deletion and TP53 mutation) Standard-risk disease: IGHV mutated (without 17p deletion and TP53 mutation) (5,6)
|
| Burkitt lymphoma |
translocation at 8q24 (MYC) with 14q32(IGH); translocations at 22q11(IGL) or 2p12 (IGK) |
MYC_translocation, including deletion of 13q, a gain of 7q, or complex cytogenetics may portend a worse prognosis Double hit mutations in ID3, CCND3, and mutations in 18q21 CN-LOH indicate a poor response to therapy and poor prognosis (29) |
| DLBCL |
rearrangements of IGH, IGK, IGL,MYC, 3q27, t(14;18) |
16q22-q24, 6p21-p25, 12q22-q24, 11q23-q25, 19q13, 1q21-q23, 8q24, and 19p13, and -17 appeared to be associated with a worse prognosis (30) |
| Follicular lymphoma |
t(14;18), abnormalities BCL6 and 3q27 |
deletions of 1p, 6q, and 17p, and gains of 7 and 12q are strongly associated with a poor prognosis also correlate with a higher risk of transformation (31) |
| Hairy cell leukemia |
BRAF V600E |
|
| MALT lymphoma |
t(11;18), t(14;18)(q32;q21), t(3;14) |
|
| Mantle cell lymphoma |
t(11;14)(q13;q32) |
Cluster C1—Best prognosis mutated IGHV, CCND1 and TP53, amplification of 11q13, and active BCR signaling Cluster C2—deletion of 11q, ATM mutations, upregulated TNF-α, NF-kB, and DNA repair pathways Cluster C3—mutations in NOTCH1, NSD2, SP140, and KMT2D; amplification of 13q; deletion of 6q; and downregulated TNF-α, NF-kB, BCR signaling, and MYC target pathways Cluster C4—Worst prognosis deletion of 13q, 17p/TP53, and 9p; TP53 mutations, complex copy number abnormalities; upregulated MYC pathways (11)
|
